Tscan Therapeutics Profit Margin

Tscan Therapeutics (TCRX) currently reports a profit margin of -2558.96% as of June 2026. That compares with -1964.88% in the prior-year period — down 30.2% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Tscan Therapeutics's profit margin history and peer comparisons.

Tscan Therapeutics's profit margin decreased from -1964.88% to -2558.96% — a 30.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics's profit margin of -2558.96% is lower than the Healthcare sector average of 14.34%. That is roughly 17938.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Tscan Therapeutics's current -2558.96% should be judged against Healthcare norms (sector average: 14.34%) and against TCRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2558.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.